Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.

ABSTRACT: Hospitalization for acute heart failure (HF) is associated with a substantial morbidity burden and with associated healthcare costs and an increased mortality risk. However, few if any major medical innovations have been witnessed in this area in recent times. Levosimendan is a first-in-class calcium sensitizer and potassium channel opener indicated for the management of acute HF. Experience in several clinical studies has indicated that administration of intravenous levosimendan in intermittent cycles may reduce hospitalization and mortality rates in patients with advanced HF; however, none of those trials were designed or powered to give conclusive insights into that possibility. This paper describes the rationale and protocol of LeoDOR (levosimendan infusions for patients with advanced

SUBMITTER: Polzl G 

PROVIDER: S-EPMC6351894 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature